BMO Capital raised its price target on Valeant Pharmaceuticals (NYSE: VRX) to $20.00 (from $17.00) while maintaining a Market Perform ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE